test
test
test

Marketing
Conferencee 2018

17 - 25 October 2018 | Tobacco Dock, London

SIGN UP FOR OUR NEWSLETTERREGISTER NOW

See you in summer for the next AMR Conference, hopefully face-to-face.

Aug 24–28
2020
delivered digitally

Novel Antimicrobials & AMR Diagnostics

AMR Conference

AMR Conference

test
test
test

Marketing
Conferencee 2018

17 - 25 October 2018 | Tobacco Dock, London

SIGN UP FOR OUR NEWSLETTERREGISTER NOW

See you in summer for the next AMR Conference, hopefully face-to-face.

Aug 24–28
2020
delivered digitally

Novel Antimicrobials & AMR Diagnostics

AMR Conference

AMR Conference

test
test
test

Marketing
Conferencee 2018

17 - 25 October 2018 | Tobacco Dock, London

SIGN UP FOR OUR NEWSLETTERREGISTER NOW

See you in summer for the next AMR Conference, hopefully face-to-face.

Aug 24–28
2020
delivered digitally

Novel Antimicrobials & AMR Diagnostics

AMR Conference

AMR Conference

test
test
test

Marketing
Conferencee 2018

17 - 25 October 2018 | Tobacco Dock, London

SIGN UP FOR OUR NEWSLETTERREGISTER NOW

See you in summer for the next AMR Conference, hopefully face-to-face.

Aug 24–28
2020
delivered digitally

Novel Antimicrobials & AMR Diagnostics

AMR Conference

AMR Conference

Individual licence

Did you miss the conference? Purchase our on-demand license and watch all 20+ sessions and panel discussions whenever you want!

Click here to get your individual licence to access all session recordings, slides and scientific poster presentations of the AMR Conference 2020.

Latest News

in the AMR and antimicrobial space

CARB-X will invest up to US$15m for German AMR projects

CARB-X announced the investment of first grants to two German research teams from the German Helmholtz…

CARB-X is funding a team of top German researchers to develop a drug to treat Staphylococcus aureus infections and prevent exacerbation of life-threatening pneumonia

Researchers from the Helmholtz Centre for Infection Research (HZI) and the Lead Discovery Center GmbH (LDC)…

CARB-X is funding a German team of scientists to develop a new treatment for difficult-to-treat Pseudomonas aeruginosa infections in cystic fibrosis patients

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) team could receive up to US$6.31 million if all…

Juvabis Announces Positive Phase 1 Results of EBL-1003 in the Innovative Medicines Initiative’s ENABLE Consortium

Single intravenous dose Phase 1 study in healthy volunteers showed that EBL-1003 (apramycin) was safe and…

World leaders join forces to fight the accelerating crisis of antimicrobial resistance

High-level global leaders group will advocate for urgent action to combat antimicrobial resistance across all sectors…

First Dynamic Dashboard analysis report and recommendations to the G20

The Global AMR R&D Hub publishes its first report “The state of public and philanthropic investments…

2020 Antimicrobial Resistance campaign: How to change the fight against AMR?

The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign. The content…

BioVersys starts Phase 1 Clinical Trial of BV100

BV100 is being developed for the treatment of serious hospital infections caused by Carbapenem resistant Acinetobacter baumannii…

CARB-X is funding Polyphor to develop a new antibiotic to treat multidrug-resistant Enterobacteriaceae Gram-negative bacterial infections

CARB-X announced today it is awarding up to US$2.62 million to Polyphor AG (SIX:POLN), headquartered in…

The #AMRconference 2020 was a great success. Almost 450 international AMR experts have participated in 26 live sessions which provided a 360 degree overview of the current AMR industry and resulted in engaging discussions.

We look forward to welcoming you again this year – hopefully face-to-face.

Here are some key takeaways from the Closing Session:

We thank our Sponsors & Partners

Supporting Partners

Media Partners

AMR Conference – What you can expect

The AMR Conference is a platform to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to market.

More than 400 participants from 25+ countries

High-level panels and expert sessions > live and on-demand

Scientific poster presentations

A wide variety of topics from financing, development & regulation

Virtual 1:1 partnering meetings

SMEs, academics & governmental agencies benefit from discounted fees

2019 Event Highlights

Event Impressions & Testimonials

More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR). The AMR Conference is a platform for SMEs, start-ups, big pharma, academia, clinicians, investors, public stakeholders and policy-makers to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market.